Developer docs
API playgroundTry for free, no card

Search company profiles

Galatea Bio

Full company profile

uuid0000gqs

Namestring
Galatea Bio
Legal namestring
Galatea Bio, Inc.
Websiteurl
galatea.bio
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Galatea Bio is a Miami Lakes, Florida-based biotechnology company founded in 2021 that builds a diversified genomic data and clinical services platform aimed at populations historically underrepresented in genetic research. The company operates a CLIA-CMS certified, CAP-accredited high-complexity molecular diagnostics laboratory that offers clinical genetic testing for neurocognitive, immunological, and cardiovascular conditions, complemented by a CAP-accredited biobank providing biospecimen storage and sample retrieval under full chain of custody. Research sequencing services run on Illumina NovaSeq X Plus and Oxford Nanopore Promethion platforms, supporting WGS, WES, lpWGS, and long-read modalities.

The company's differentiator is its proprietary AI/ML stack applied to ancestry inference and polygenic risk scoring. Algorithms include Gnomix for high-resolution ancestry deconvolution, Neural ADMIXTURE (a neural-network autoencoder that reduces population genetics compute from approximately one month to hours), Archetypal Analysis for population clustering, and an ancestry-adjusted PRS (aaPRS) framework that personalizes model selection per individual and recalibrates for ancestry. These are wrapped into the StrataRisk™ SaaS platform launched in March 2025 and feed the Biobank of the Americas research initiative, which targets 10 million samples from diverse ancestries and currently claims access to 500K+ geno:pheno records with a 60%+ non-European diversity index.

Galatea generates revenue through four streams: clinical genetic testing (per-test reimbursement via a self-serve portal), biopharma R&D partnerships built around large-scale population sequencing consortiums with academic universities and health systems globally, biobanking services for research programs, and a growing platform/data-access layer including the new StrataRisk™ subscription SaaS. Pricing is quote-based and not publicly disclosed. Customer segments are biopharma/life sciences, academic and research institutions, healthcare providers, and health systems. Strategic partnerships with Stanford University, the Chan Zuckerberg Initiative, DNAnexus, Fabric Genomics, and Genetic Alliance's iHope network underpin both technology integration and sample acquisition. The company has raised approximately $33M-$45M across four rounds since 2021, with a $25M financing in March 2025 led by a 12-investor syndicate.

Short descriptiontext

Galatea Bio is a CLIA-certified biotech that combines a diverse genomic biobank with proprietary AI algorithms for ancestry inference and polygenic risk scoring, serving biopharma, academic researchers, and clinicians focused on underrepresented populations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiami Lakes, United States
HQ citystring
Miami Lakes
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical genomic testing, polygenic risk scoring, biobanking services, population genomics, ancestry-adjusted PRS
Industry3 codes
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Genomic Services & Precision Medicine
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Clinical Testing & Genomic Services
TypeSubscription Recurring
Description

CLIA-CMS certified, CAP-accredited molecular diagnostics laboratory offering genetic testing services to physicians and healthcare providers. Testing catalog empowers exploration of genetic variation for various diseases including neurocognitive, immunological, and cardiovascular conditions.

galatea.bio
2Biopharma R&D Partnerships
TypeProfessional Services
Description

Partnerships with pharmaceutical and life sciences organizations to build large-scale population sequencing programs in partnership with academic universities and health systems globally.

galatea.bio
3Biobank Services
TypeManaged Services
Description

Biospecimen storage solutions, sample retrieval, and associated data storage services for research programs. CAP accredited biobank with storage at controlled temperatures and full chain of custody.

galatea.bio
4Platform & Data Access
TypeSubscription Recurring
Description

Access to genomic-phenotypic data lake and bioinformatics analysis platform for research and discovery purposes.

galatea.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Biobank of the Americas
Description

A Galatea-led research initiative that aims to build a global clinico-genomics database to facilitate diversity in association studies, polygenic and phenomic risk scoring models, and precision medicine implementations.

galatea.bio
+1 more record
Core offering1 text field

Galatea Bio operates a CLIA-CMS certified and CAP-accredited high-complexity molecular diagnostics clinical laboratory providing clinical genetic testing and genomic services to physicians and healthcare providers. The company also offers research sequencing services using Illumina NovaSeq X Plus and Oxford Nanopore long-read platforms, CAP-accredited biobanking services, and the Biobank of the Americas research initiative, all powered by proprietary AI/ML algorithms for ancestry inference and ancestry-adjusted polygenic risk scoring.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Galatea Bio is a biotechnology company offering an integrated platform of precision health products and services focused on genetic diversity. The core offerings include a CLIA-certified clinical testing laboratory providing molecular diagnostics and genomic services, research sequencing using Illumina and Oxford Nanopore platforms, and CAP-accredited biobanking with storage solutions. The platform integrates proprietary AI-powered bioinformatics including Ancestry Inference (Gnomix) and Ancestry-adjusted Polygenic Risk Scores (aaPRS), supported by the Biobank of the Americas research initiative. Recent product launches include StrataRisk™, a PRS SaaS platform for common disease risk assessment. Partnerships with DNAnexus and Fabric Genomics extend technical capabilities for cloud-based genomic analysis and integrated rare variant/PRS testing.

Product and service6 records
1Clinical Testing & Genomic Services
CategoryClinical Genomics
Description

Full-stack next-generation sequencing molecular diagnostics clinical laboratory and biobank (CLIA-CMS certified, CAP-accredited high-complexity lab) offering a testing catalog that empowers physicians to explore genetic variation and pathways of biological importance. Used by healthcare providers and physicians for clinical genetic testing and patient disease risk assessment.

2Research Sequencing Services
CategoryResearch Genomics Services
Description

Cost-effective sequencing services for research programs using Illumina NovaSeq X Plus (WGS, WES, WES+DP, lpWGS) and Oxford Nanopore long-read sequencing platforms from a CLIA/CAP lab. Enables participants to receive genetic incidental findings reports where protocol allows. Targeted at academic institutions and biopharma research programs.

3Biobanking Services
CategoryBiobanking Services
Description

CAP-accredited biobank offering storage solutions for biological specimens at controlled ambient temperatures (4-30-80-100°C) with redundant backup systems, automated temperature monitoring, sample retrieval with full chain of custody, and associated phenotypic/clinical data storage. Used by research programs and biopharma partners.

4Biobank of the Americas (BBofA)
CategoryResearch Consortium / Population Genomics Initiative
Description

Galatea-led research initiative building a global clinico-genomics database to facilitate diversity in association studies, polygenic and phenomic risk scoring models, and precision medicine implementations. Develops custom disease-specific cohorts composed of diverse participants with associated healthcare record data, with a target of mapping genetic diversity of 10 million individuals.

5StrataRisk Polygenic Risk Score Platform
CategoryPrecision Medicine Software / SaaS
Description

Polygenic Risk Score (PRS) Software-as-a-Service (SaaS) platform designed to assess the polygenic contribution to common diseases such as cardiovascular, metabolic disorders, and cancer susceptibility. Used by healthcare providers and clinical laboratories to scale common disease risk assessment and reporting at population scale.

6Platform & Data Science
CategoryData & Bioinformatics Platform
Description

Platform leveraging one of the largest private genomic-phenotypic data lakes (500K+ records, 60%+ non-European diversity) and a world-class team of population geneticists and bioinformatics experts. Provides biopharma and life sciences organizations access to large-scale population sequencing program consortiums in partnership with academic universities and health systems globally.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-24
Description

Collaboration to enhance and deliver comprehensive genetic testing for assessing individual susceptibility to common diseases. Integrates analysis of rare genetic variants and polygenic risk scoring (PRS) for broader risk assessment across populations of all ancestries.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-22
Description

Galatea joined the iHope Genetic Health (iGH) network to expand free genomic testing for underserved families worldwide. Partnership advances global health equity through precision medicine for communities historically underrepresented in genetic research.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-08-14
Description

Partnership to advance precision medicine for underserved populations by integrating Galatea's diverse genomic datasets with DNAnexus' cloud platform. Aims to enhance access to advanced genetic tools, improving diagnostics, drug discovery, and health outcomes particularly in Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership providing access to latest technology in genetic research and analysis. Enables Galatea to stay at forefront of genetic research and leverage Stanford's research infrastructure.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership providing technology access and support for genetic research initiatives focused on underrepresented populations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Consumer and clinical genetic testing platform with massive genotyped cohort and biopharma data licensing. Competes with Galatea in ancestry-aware genetic insights and pharma partnerships, though at vastly larger scale.

TypeDirect peer
Description

Clinical genetic testing company offering hereditary cancer and population health tests to providers and employers. Directly comparable CLIA-certified lab service model and biopharma-adjacent strategy.

TypeDirect peer
Description

DNA sequencing platform operating a CLIA lab and population genomics programs with health systems. Directly comparable end-to-end sequencing-as-a-service and population health analytics approach.

4Genomic Prediction
TypeDirect peer
Description

Polygenic risk score company focused on embryo selection and disease risk assessment. Direct PRS-focused competitor with overlapping clinical genetic testing ambitions.

TypeBroad incumbent
Description

Established clinical genetic testing leader with deep payer relationships and broad hereditary disease and oncology menu. Competes in clinical testing market; ex-CSO Jerry Lanchbury is a Galatea scientific advisor.

TypeBroad incumbent
Description

Public genetic testing company specializing in reproductive health and oncology. Competes in clinical genomics space and represents a scaled, well-capitalized reference for Galatea's CLIA-lab service model.

TypeBroad incumbent
Description

Major clinical laboratory network offering extensive genetic and molecular diagnostics. Represents the consolidated incumbent against which Galatea must differentiate on diversity and PRS quality.

TypeBroad incumbent
Description

Large reference lab with genetic and advanced diagnostics offerings. Competes broadly in clinical testing market with national logistics and payer contracts.

TypeEmerging player
Description

UK-based genomics company focused on polygenic risk scores for biopharma and health systems. Comparable PRS-led, biopharma-services business model with strong academic provenance.

TypeBroad incumbent
Description

Iceland-based population genetics pioneer (Amgen subsidiary) operating one of the world's most deeply phenotyped population biobanks. Comparable population-genomics + pharma-discovery model, though at far greater scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Galatea Bio

Genomic Services & Precision Medicinegalatea.bio

Galatea Bio is a CLIA-certified biotech that combines a diverse genomic biobank with proprietary AI algorithms for ancestry inference and polygenic risk scoring, serving biopharma, academic researchers, and clinicians focused on underrepresented populations.

What Galatea Bio does

Galatea Bio is a Miami Lakes, Florida-based biotechnology company founded in 2021 that builds a diversified genomic data and clinical services platform aimed at populations historically underrepresented in genetic research. The company operates a CLIA-CMS certified, CAP-accredited high-complexity molecular diagnostics laboratory that offers clinical genetic testing for neurocognitive, immunological, and cardiovascular conditions, complemented by a CAP-accredited biobank providing biospecimen storage and sample retrieval under full chain of custody. Research sequencing services run on Illumina NovaSeq X Plus and Oxford Nanopore Promethion platforms, supporting WGS, WES, lpWGS, and long-read modalities.

The company's differentiator is its proprietary AI/ML stack applied to ancestry inference and polygenic risk scoring. Algorithms include Gnomix for high-resolution ancestry deconvolution, Neural ADMIXTURE (a neural-network autoencoder that reduces population genetics compute from approximately one month to hours), Archetypal Analysis for population clustering, and an ancestry-adjusted PRS (aaPRS) framework that personalizes model selection per individual and recalibrates for ancestry. These are wrapped into the StrataRisk™ SaaS platform launched in March 2025 and feed the Biobank of the Americas research initiative, which targets 10 million samples from diverse ancestries and currently claims access to 500K+ geno:pheno records with a 60%+ non-European diversity index.

Galatea generates revenue through four streams: clinical genetic testing (per-test reimbursement via a self-serve portal), biopharma R&D partnerships built around large-scale population sequencing consortiums with academic universities and health systems globally, biobanking services for research programs, and a growing platform/data-access layer including the new StrataRisk™ subscription SaaS. Pricing is quote-based and not publicly disclosed. Customer segments are biopharma/life sciences, academic and research institutions, healthcare providers, and health systems. Strategic partnerships with Stanford University, the Chan Zuckerberg Initiative, DNAnexus, Fabric Genomics, and Genetic Alliance's iHope network underpin both technology integration and sample acquisition. The company has raised approximately $33M-$45M across four rounds since 2021, with a $25M financing in March 2025 led by a 12-investor syndicate.

Galatea Bio firmographics

Firmographics
Name
Galatea Bio
Legal name
Galatea Bio, Inc.
Website
https://galatea.bio
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Galatea Bio is a CLIA-certified biotech that combines a diverse genomic biobank with proprietary AI algorithms for ancestry inference and polygenic risk scoring, serving biopharma, academic researchers, and clinicians focused on underrepresented populations.
Ownership category
akta.pro rank

Galatea Bio industry classification

Industry
Product category
Genomic Services & Precision Medicine
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Clinical genomic testing
  • Polygenic risk scoring
  • Biobanking services
  • Population genomics
  • Ancestry-adjusted PRS

Where Galatea Bio is headquartered

Location

Headquarters

HQ city
Miami Lakes
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Galatea Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Clinical Testing & Genomic Services: CLIA-CMS certified, CAP-accredited molecular diagnostics laboratory offering genetic testing services to physicians and healthcare providers. Testing catalog empowers exploration of genetic variation for various diseases including neurocognitive, immunological, and cardiovascular conditions.
  2. Biopharma R&D Partnerships: Partnerships with pharmaceutical and life sciences organizations to build large-scale population sequencing programs in partnership with academic universities and health systems globally.
  3. Biobank Services: Biospecimen storage solutions, sample retrieval, and associated data storage services for research programs. CAP accredited biobank with storage at controlled temperatures and full chain of custody.
  4. Platform & Data Access: Access to genomic-phenotypic data lake and bioinformatics analysis platform for research and discovery purposes.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Galatea Bio product offering

Product offering

Core offering

Galatea Bio operates a CLIA-CMS certified and CAP-accredited high-complexity molecular diagnostics clinical laboratory providing clinical genetic testing and genomic services to physicians and healthcare providers. The company also offers research sequencing services using Illumina NovaSeq X Plus and Oxford Nanopore long-read platforms, CAP-accredited biobanking services, and the Biobank of the Americas research initiative, all powered by proprietary AI/ML algorithms for ancestry inference and ancestry-adjusted polygenic risk scoring.

Product overview

Galatea Bio is a biotechnology company offering an integrated platform of precision health products and services focused on genetic diversity. The core offerings include a CLIA-certified clinical testing laboratory providing molecular diagnostics and genomic services, research sequencing using Illumina and Oxford Nanopore platforms, and CAP-accredited biobanking with storage solutions. The platform integrates proprietary AI-powered bioinformatics including Ancestry Inference (Gnomix) and Ancestry-adjusted Polygenic Risk Scores (aaPRS), supported by the Biobank of the Americas research initiative. Recent product launches include StrataRisk™, a PRS SaaS platform for common disease risk assessment. Partnerships with DNAnexus and Fabric Genomics extend technical capabilities for cloud-based genomic analysis and integrated rare variant/PRS testing.

Differentiator

Problem solved

Functional benefit

Brands

  • Biobank of the Americas: A Galatea-led research initiative that aims to build a global clinico-genomics database to facilitate diversity in association studies, polygenic and phenomic risk scoring models, and precision medicine implementations.
  • StrataRisk™

Products and services

  • Clinical Testing & Genomic Services Full-stack next-generation sequencing molecular diagnostics clinical laboratory and biobank (CLIA-CMS certified, CAP-accredited high-complexity lab) offering a testing catalog that empowers physicians to explore genetic variation and pathways of biological importance. Used by healthcare providers and physicians for clinical genetic testing and patient disease risk assessment.
  • Research Sequencing Services Cost-effective sequencing services for research programs using Illumina NovaSeq X Plus (WGS, WES, WES+DP, lpWGS) and Oxford Nanopore long-read sequencing platforms from a CLIA/CAP lab. Enables participants to receive genetic incidental findings reports where protocol allows. Targeted at academic institutions and biopharma research programs.
  • Biobanking Services CAP-accredited biobank offering storage solutions for biological specimens at controlled ambient temperatures (4-30-80-100°C) with redundant backup systems, automated temperature monitoring, sample retrieval with full chain of custody, and associated phenotypic/clinical data storage. Used by research programs and biopharma partners.
  • Biobank of the Americas (BBofA) Galatea-led research initiative building a global clinico-genomics database to facilitate diversity in association studies, polygenic and phenomic risk scoring models, and precision medicine implementations. Develops custom disease-specific cohorts composed of diverse participants with associated healthcare record data, with a target of mapping genetic diversity of 10 million individuals.
  • StrataRisk Polygenic Risk Score Platform Polygenic Risk Score (PRS) Software-as-a-Service (SaaS) platform designed to assess the polygenic contribution to common diseases such as cardiovascular, metabolic disorders, and cancer susceptibility. Used by healthcare providers and clinical laboratories to scale common disease risk assessment and reporting at population scale.
  • Platform & Data Science Platform leveraging one of the largest private genomic-phenotypic data lakes (500K+ records, 60%+ non-European diversity) and a world-class team of population geneticists and bioinformatics experts. Provides biopharma and life sciences organizations access to large-scale population sequencing program consortiums in partnership with academic universities and health systems globally.

Companies that use Galatea Bio

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Galatea Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability9 records

Feature6 records

Galatea Bio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Fabric GenomicscoreTechnology or Integration · 24 June 2025Collaboration to enhance and deliver comprehensive genetic testing for assessing individual susceptibility to common diseases. Integrates analysis of rare genetic variants and polygenic risk scoring (PRS) for broader risk assessment across populations of all ancestries.
  • Genetic Alliance (iHope Genetic Health Program)coreStrategic or Co-development Partner · 22 April 2025Galatea joined the iHope Genetic Health (iGH) network to expand free genomic testing for underserved families worldwide. Partnership advances global health equity through precision medicine for communities historically underrepresented in genetic research.
  • DNAnexuscoreTechnology or Integration · 14 August 2024Partnership to advance precision medicine for underserved populations by integrating Galatea's diverse genomic datasets with DNAnexus' cloud platform. Aims to enhance access to advanced genetic tools, improving diagnostics, drug discovery, and health outcomes particularly in Latin America.
  • Stanford UniversitycoreStrategic or Co-development PartnerAcademic partnership providing access to latest technology in genetic research and analysis. Enables Galatea to stay at forefront of genetic research and leverage Stanford's research infrastructure.
  • Chan Zuckerberg InitiativecoreStrategic or Co-development PartnerStrategic partnership providing technology access and support for genetic research initiatives focused on underrepresented populations.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Galatea Bio competitors and assessment

Company assessment

Direct peers

  • 23andMe: Consumer and clinical genetic testing platform with massive genotyped cohort and biopharma data licensing. Competes with Galatea in ancestry-aware genetic insights and pharma partnerships, though at vastly larger scale.
  • Color Genomics: Clinical genetic testing company offering hereditary cancer and population health tests to providers and employers. Directly comparable CLIA-certified lab service model and biopharma-adjacent strategy.
  • Helix: DNA sequencing platform operating a CLIA lab and population genomics programs with health systems. Directly comparable end-to-end sequencing-as-a-service and population health analytics approach.
  • Genomic Prediction: Polygenic risk score company focused on embryo selection and disease risk assessment. Direct PRS-focused competitor with overlapping clinical genetic testing ambitions.

Broad incumbents

  • Myriad Genetics: Established clinical genetic testing leader with deep payer relationships and broad hereditary disease and oncology menu. Competes in clinical testing market; ex-CSO Jerry Lanchbury is a Galatea scientific advisor.
  • Natera: Public genetic testing company specializing in reproductive health and oncology. Competes in clinical genomics space and represents a scaled, well-capitalized reference for Galatea's CLIA-lab service model.
  • Labcorp: Major clinical laboratory network offering extensive genetic and molecular diagnostics. Represents the consolidated incumbent against which Galatea must differentiate on diversity and PRS quality.
  • Quest Diagnostics: Large reference lab with genetic and advanced diagnostics offerings. Competes broadly in clinical testing market with national logistics and payer contracts.
  • deCODE genetics: Iceland-based population genetics pioneer (Amgen subsidiary) operating one of the world's most deeply phenotyped population biobanks. Comparable population-genomics + pharma-discovery model, though at far greater scale.

Emerging players

  • Genomics plc: UK-based genomics company focused on polygenic risk scores for biopharma and health systems. Comparable PRS-led, biopharma-services business model with strong academic provenance.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Galatea Bio social profiles

Digital presence

Galatea Bio compliance and trust

Trust signal

Compliance2 records

Galatea Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Galatea Bio leadership team

Management profile

Number of profiles

Profiles12 records

Galatea Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Galatea Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galatea Bio

What does Galatea Bio do?

Galatea Bio operates a CLIA-CMS certified and CAP-accredited high-complexity molecular diagnostics clinical laboratory providing clinical genetic testing and genomic services to physicians and healthcare providers. The company also offers research sequencing services using Illumina NovaSeq X Plus and Oxford Nanopore long-read platforms, CAP-accredited biobanking services, and the Biobank of the Americas research initiative, all powered by proprietary AI/ML algorithms for ancestry inference and ancestry-adjusted polygenic risk scoring.

Is Galatea Bio a public or private company?

Galatea Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Galatea Bio founded?

Galatea Bio was founded in 2020. It employs 11 to 50 people.

Where is Galatea Bio based?

Galatea Bio is headquartered in Miami Lakes, United States, in the North America region.

How does Galatea Bio make money?

Four revenue lines are on record. Clinical Testing & Genomic Services are the primary driver. The others are biopharma R&D Partnerships, biobank Services and platform & Data Access.

Who are Galatea Bio's main competitors?

Direct peers on record are 23andMe, Color Genomics, Helix and Genomic Prediction. Broad incumbents are Myriad Genetics, Natera, Labcorp, Quest Diagnostics and deCODE genetics. Genomics plc is listed as an emerging player.

Does Galatea Bio have an API?

No public API is recorded for Galatea Bio.

What industry is Galatea Bio in?

Galatea Bio's product category is Genomic Services & Precision Medicine. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogGalatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common DiseasesGalatea Bio and Fabric Genomics announced a collaboration to combine rare pathogenic variant analysis with polygenic risk scoring for common diseases. The initial offering includes an inherited cardiovascular gene panel with PRS for traits like coronary arterial disease and hypertension. A follow-up will integrate hereditary cancer panels with PRS for breast, colorectal, and prostate cancers.YahooGalatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common DiseasesGalatea Bio and Fabric Genomics announced a collaboration to combine rare variant analysis with polygenic risk scoring for common diseases. The initial offering includes an inherited cardiovascular gene panel and PRS for traits like coronary disease and hypertension. A follow-up will integrate hereditary cancer panels with PRS for breast, colorectal, and prostate cancers.Business & FinancialGalatea Bio Joins Ihope Genetic Health Program, Expanding Access To Genomic Testing For Underserved FamiliesGalatea Bio joined the iHope Genetic Health program to expand free genomic testing for underserved families. The partnership will enhance diagnostic capabilities for undiagnosed individuals with suspected rare genetic diseases in low- and middle-income communities. Galatea Bio plans to enroll millions of participants in its Galatea Global Biobank.Biobanking.comGalatea Bio Secures $25M to Expand Global Biobank for Diverse Genomic ResearchGalatea Bio has secured $25 million in funding to expand its Galatea Global Biobank, aiming to sequence 10 million participants with a focus on non-European ancestries. The company will utilize this capital to enhance high-throughput sequencing capabilities and deploy AI-driven tools like the StrataRisk Polygenic Risk Score API to improve genetic risk predictions for diverse populations.AI InsiderGalatea Bio Attracts $25M Investment to Advance AI-Based Genomic SolutionsGalatea Bio raised $25 million in funding to expand its clinico-genomics platform. The round included investments from F-Prime, Helios Digital Ventures, and others. The company will use the funds to support multi-modal data integration and AI-driven applications for precision medicine.Refresh MiamiGalatea Bio secures $25M to help transform global genomic research and precision medicineGalatea Bio raised $25 million to expand its biobank into the Galatea Global Biobank, aiming to sequence 10 million participants worldwide. The funding will support sequencing, AI-powered genomic analysis, and partnerships to refine genetic risk analysis for complex diseases.GlobeNewswireGalatea Bio Secures $25M to Develop Global Biobank and Enable Precision Health at Scale for AllGalatea Bio has secured $25 million in funding to expand its global biobank and advance genomic research, focusing on increasing diversity among its participants. The company aims to develop more accurate genetic risk predictions and disease models by including non-European ancestries in its datasets. The funding supports expanding sequencing capabilities and partnerships to accelerate personalized healthcare.GalateaGalatea Bio gets $25M to map genetic diversity of 10 million people, help pharma create new medicinesGalatea Bio secured $25 million in funding to map the genetic diversity of 10 million individuals. The initiative aims to assist pharmaceutical companies in developing new medicines by providing a comprehensive understanding of genetic variations across diverse populations.TradingViewGalatea Bio Secures $25M to Develop Global Biobank and Enable Precision Health at Scale for AllGalatea Bio secured $25 million in funding to expand its biobank into a global initiative sequencing 10 million participants, focusing on non-European ancestry. The company will use the funds for high-throughput sequencing, AI-driven analysis, and partnerships with Illumina and Oxford Nanopore.Business InsiderGalatea Bio Secures $25M to Develop Global Biobank and Enable Precision Health at Scale for AllGalatea Bio secured $25 million in funding to expand its biobank to 10 million participants, focusing on non-European ancestry. The company will use the funds for high-throughput sequencing, AI-driven genomic analysis, and partnerships with Illumina and Oxford Nanopore.